Authors: Scripture, CD Pieper, JA

Citation: Cd. Scripture et Ja. Pieper, Clinical pharmacokinetics of fluvastatin, CLIN PHARMA, 40(4), 2001, pp. 263-281

Authors: Pieper, JA

Citation: Ja. Pieper, Pharmacologic interventions for coronary artery disease and risk factors -Introduction, PHARMACOTHE, 21(9), 2001, pp. 189S-189S

Authors: Pieper, JA

Citation: Ja. Pieper, Management of coronary heart disease risk factors and progression with calcium channel blockers, PHARMACOTHE, 21(9), 2001, pp. 195S-208S

Authors: McCune, JS Lindley, C Decker, JL Williamson, KM Meadowcroft, AM Graff, D Sawyer, WT Blough, DK Pieper, JA

Citation: Js. Mccune et al., Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan, J CLIN PHAR, 41(7), 2001, pp. 723-731

Authors: Graff, DW Williamson, KM Pieper, JA Carson, SW Adams, KF Cascio, WE Patterson, JH

Citation: Dw. Graff et al., Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients, J CLIN PHAR, 41(1), 2001, pp. 97-106

Authors: Meadowcroft, AM Williamson, KM Patterson, JH Hinderliter, AL Pieper, JA

Citation: Am. Meadowcroft et al., The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers, J CLIN PHAR, 39(4), 1999, pp. 418-424